- Q1 2024 Madrigal Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2024$219 (-3.39%)Earnings
- Madrigal Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Madrigal Pharmaceuticals Inc at UBS BioPharma Conference TranscriptNov 08, 2023
- Madrigal Pharmaceuticals Inc Phase 3 MAESTRO-NASH Trial Investor Call TranscriptJun 24, 2023
- Madrigal Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Madrigal Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Madrigal Pharmaceuticals Inc at JMP Securities Life Sciences Conference TranscriptMay 16, 2023
- Madrigal Pharmaceuticals Inc to Announce Topline Data from the Phase 3 MAESTRO-NASH Study of Resmetirom Presentation TranscriptDec 19, 2022
- Madrigal Pharmaceuticals Inc EASL Investor Event Call TranscriptJun 25, 2022
- Madrigal Pharmaceuticals Inc at JMP Securities Life Sciences Conference TranscriptJun 15, 2022
- Madrigal Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Madrigal Pharmaceuticals Inc at UBS Global Healthcare Conference TranscriptMay 24, 2022
- Q1 2022 Madrigal Pharmaceuticals Inc Earnings Call TranscriptMay 09, 2022$95.17Earnings
- Madrigal Pharmaceuticals Inc Call to Discuss MAESTRO-NAFLD-1 Phase 3 Data TranscriptJan 31, 2022
- Madrigal Pharmaceuticals Inc AASLD The Liver Meeting Call TranscriptNov 16, 2021
- Madrigal Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Madrigal Pharmaceuticals Inc at UBS Global Healthcare Virtual Conference TranscriptMay 24, 2021
- Madrigal Pharmaceuticals Inc at UBS Global Healthcare Conference (Virtual) TranscriptMay 19, 2020
Madrigal Pharmaceuticals Inc Phase 3 MAESTRO-NASH Trial Investor Call Transcript
So good evening, and thanks for joining Madrigal's EASL Investor Event and Webcast. With me today in Vienna are Dr. Becky Taub, President of R&D and Chief Medical Officer; and Dr. Stephen Harrison, lead investigator of our Phase III MISO studies of resmetirom. Fine print. These are our forward-looking statements. I'd ask you to see Thursday's press release and our recent SEC filings for risk factor considerations associated with these statements and our business. We'd like to express our thanks to EASL for selecting -- the pivotal Phase III MAESTRO-NASH trial of resmetirom is the first abstract to open Thursday general session of the Congress. The presentation signaled an important milestone for Madrigal and the Nash field. And based on the positive feedback and words of encouragement we received from thought leaders, community clinicians and our other stakeholders after the presentation. I believe that the MAESTRO-NASH data set the tone for the meeting.
Before Becky and Stephen Harrison review the detailed that, I'd like
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)